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Abstract
NSCLC (non-small cell lung cancer) often exhibits resistance to paclitaxel treatment. Identifying the elements regulating
paclitaxel response will advance efforts to overcome such resistance in NSCLC therapy. Using in vitro approaches, we
demonstrated that over-expression of the microRNA miR-337-3p sensitizes NCI-H1155 cells to paclitaxel, and that miR-337-
3p mimic has a general effect on paclitaxel response in NSCLC cell lines, which may provide a novel adjuvant strategy to
paclitaxel in the treatment of lung cancer. By combining in vitro and in silico approaches, we identified STAT3 and RAP1A as
direct targets that mediate the effect of miR-337-3p on paclitaxel sensitivity. Further investigation showed that miR-337-3p
mimic also sensitizes cells to docetaxel, another member of the taxane family, and that STAT3 levels are significantly
correlated with taxane resistance in lung cancer cell lines, suggesting that endogenous STAT3 expression is a determinant
of intrinsic taxane resistance in lung cancer. The identification of a miR-337-3p as a modulator of cellular response to
taxanes, and STAT3 and RAP1A as regulatory targets which mediate that response, defines a novel regulatory pathway
modulating paclitaxel sensitivity in lung cancer cells, which may provide novel adjuvant strategies along with paclitaxel in
the treatment of lung cancer and may also provide biomarkers for predicting paclitaxel response in NSCLC.
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Introduction
Paclitaxel is a microtubule-targeting agent initially isolated from
the conifer Taxus brevifolia – the yew tree has a long history of
medicinal uses [1] – and is widely used in the treatment of human
cancers, including lung cancer. For NSCLC, resistance to
paclitaxel is common, with response rates ranging from 21% to
24% [2,3]. Mechanisms for such resistance include over-expres-
sion of P-glycoprotein, alterations in tubulin composition, and
mutations in b-tubulin [4,5,6,7]. A recent study indicated that a
large group of protein-coding genes belonging to a wide range of
functional classes is potentially involved in modulating paclitaxel
resistance in cancer treatment [8]. Identifying the mechanisms
regulating the expression of key genes involved in paclitaxel
resistance will advance efforts to overcome such resistance in the
treatment of lung cancer.
We are interested in the potential involvement of microRNAs
(miRNAs) in modulating paclitaxel response in lung cancer
treatment. miRNAs are short, 19 to 23 nucleotide RNAs found
in multiple organisms that regulate gene expression largely by
decreasing levels of target messenger RNAs [9,10] and have been
shown to play important roles in regulating a broad range of
pathological processes, including cancer pathogenesis. miRNA
levels can be easily manipulated using synthetic RNA molecules. A
chemically stabilized, single-stranded RNA molecule complemen-
tary to a target miRNA acts as an inhibitor and decreases
endogenous levels of the miRNA. Conversely, a double-stranded
RNA molecule with one strand identical in sequence to a mature
miRNA acts as a mimic of the naturally occurring miRNA and
increases its cellular expression levels. Several studies have
explored the therapeutic effects of miRNA mimics and inhibitors
and demonstrated the potential of these classes of oligonucleotides
as therapeutic agents [11,12,13,14,15,16].
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chromosome 14q32.2. miR-337-3p is highly expressed in normal
immortalized fetal lung fibroblasts (IMR-90), and detectable in
immortalized human bronchial epithelial cells (HBECs). The
expression of miR-337-3p in lung cancer lines, however, is
generally lower than in normal lung epithelial cell lines
(Figure S1). Target prediction shows that miR-337-3p potentially
regulates the expression of multiple genes that have been
implicated in tumorigenesis. We found that miR-337-3p sensitizes
lung cancer cells to paclitaxel treatment, but unexpectedly, does
not significantly affect cell viability alone. We further used in vitro
and in silico approaches to define the direct targets of miR-337-3p
that mediate its effect on paclitaxel sensitivity. We also explored
the potential relevance of miR-337-3p mimic and its targets in
determining paclitaxel sensitivity in a large panel of NSCLC cell
lines, and preliminarily explored the potential of miR-337-3p
mimic as an adjuvant to paclitaxel treatment in vitro in NSCLC cell
lines.
Materials and Methods
Cell lines
Cell lines used in this study were obtained from the Hamon
Center for Therapeutic Oncology Research at UT Southwestern
Medical Center. Lines beginning with ‘‘NCI-H’’ were established
at the National Cancer Institute [17,18]. Lines beginning with
‘‘HCC’’ and HBECs were established by the Hamon Center for
Therapeutic Oncology Research at UT Southwestern Medical
Center [19]. All lung cancer cell lines were grown in RPMI-1640
medium (Life Technologies, Carlsbad, CA) supplemented with 5%
fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA).
HBECs were grown in GIBCOH KSFM medium supplemented
with bovine pituitary extract and recombinant human epidermal
growth factor (Life Technologies). All cell lines were DNA
fingerprinted using the GenePrint PowerPlex 1.2 system (Pro-
mega, Madison, WI) and confirmed against fingerprint libraries
maintained by ATCC and the Minna/Gazdar laboratory, and
tested for contamination using the e-Myco Mycoplasma PCR
detection Kit (Boca Scientific, Boca Raton, FL).
Cell viability assays
Sensitivity of NSCLC cell lines to paclitaxel and docetaxel was
measured using a standard protocol as described in Zhou et al.
[20]. Briefly, cells were plated in 96-well format, with paclitaxel
added in different concentrations after 24 h, followed by
incubation with drug for 96 h. Cell viability was determined using
the CellTiter 96H AQueous One Solution Cell Proliferation Assay
(MTS, Promega). The effect of miR-337-3p and its targets were
determined by transient transfection of either miR-337-3p mimic
or siRNA oligos targeting specific genes. In general, cells were
reverse-transfected with the indicated oligos in 96-well format and
cultured for 72 h, followed by incubation with drugs for additional
72 h. Cell viability was determined using the CellTiter 96H
AQueous One Solution Cell Proliferation Assay (MTS, Promega)
or the CellTiter-Glo Luminescent Cell Viability Assay (ATP,
Promega).
Flow cytometry
Cells were transfected with the indicated oligos in 6-well plates
for 48 h, followed by treatment with either paclitaxel or carrier for
an additional 16 h. Both detached and attached cells were
centrifuged at 1000 rpm for 5 min. The cells were washed once
with 1X PBS (phosphate buffered saline) and fixed with 1X PBS
containing 1 mM EDTA and 85% ethanol at 4uC. After 1 h, the
cells were harvested by centrifugation at 1400 rpm for 5 min at
4uC. The cells were resuspended in 1X PBS, and treated with
50 mg/ml propidium iodide and 100 mg/ml RNase A for 30 min
at 37uC. Cell cycle data were collected on a Cytomics FC 500 flow
cytometer (Beckman Coulter, Brea, CA), with 20,000 events
collected per sample. Data were evaluated using the FlowJo data
analysis software, version 9.1 (TreeStar, Ashland, OR).
Quantitative RT-PCR (qRT-PCR)
miRNA expression was measured on an ABI PRISM 7900
Sequence Detection System using TaqManH microRNA Assays
(Life Technologies) with RNU19 RNA expression as an internal
control for normalization of RNA loading. mRNA expression was
measured using TaqManH Gene Expression Assays with GAPDH
mRNA expression as an internal control. Threshold cycle times
(Ct) were obtained and relative gene expression was calculated
using the comparative cycle time method.
Western blots
Cell lysates were prepared using NP-40 buffer. Protein
concentration was determined using the Pierce BCA assay
(Thermo Fisher, Rockford, IL). For electrophoresis, equal amounts
of cell lysate were resolved by SDS-PAGE and transferred to
Immun-Blot PVDF membranes (Bio-Rad, Hercules, CA). Mem-
branes were blocked and probed with the following antibodies:
rabbit anti-RAP1A or anti-STAT3 (Cell Signaling Technology,
Beverly, MA), or goat anti-actin (Santa Cruz Biotechnology, Santa
Cruz, CA). Bound antibodies were detected with secondary
antibodies conjugated with horseradish peroxidase (HRP) (Santa
Cruz Biotechnology) and visualized by enhanced chemilumines-
cent (ECL) substrate (Thermo Fisher). Relative changes in protein
levels were quantified by densitometry using the Quantity One
software (Bio-Rad).
miRNA target prediction
To identify the regulatory targets of miR-337-3p, we used the
miRmate method developed in our lab as described previously
[21]. Briefly, the method rewards complete complementarity at
positions 2–8 of the miRNA (the seed region), mismatches and
insertions in the central bulge at positions 9–11 of the miRNA,
some complementarity at the 39 end, and specific sequence
composition at positions 1 (A) and 9 (A or C) of the miRNA,
according to the findings of Lewis et al. [22].
Luciferase reporter assays
The segment of the wildtype (WT) 39UTRs containing the
predicted target sites of RAP1A (NM_002884) and STAT3
(NM_003150) were cloned downstream of the luciferase cDNA
in pMIR-REPORT (Ambion, Austin, TX), a vector that contains
both luciferase and b-galactosidase cDNAs under the control of
separate mammalian promoter/terminator systems. The mutant
constructs (RAP1A MU and STAT3 MU) with position 3 (the 2
nd
nucleotide in the target seed sequence) changed from G to A and
position 1 (immediately 39 to the seed sequence) changed from A
to U, were made using the QuikChange Site Directed Mutagenesis
Kit (Stratagene, La Jolla, CA). Luciferase activity and b-
galactosidase activity were measured using the Luciferase Assay
System and b-galactosidase Assay System (Promega), respectively.
mRNA expression profiling
NCI-H1155 cells were transfected with miR-337-3p mimic or
negative control mimic. Total RNA was isolated using mirVana
TM
miRNA Isolation Kit (Ambion), labeled and hybridized to
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CA) using standard protocols. Slides were scanned on an Illumina
BeadStation and signal intensities were summarized using
BeadStudio v3.3 (Illumina). Background subtraction and quantile
normalization were performed using the MBCB algorithm [23].
Correlation of expression with 39UTR motif content
Correlation between changes in gene expression induced by
miR-337-3p over-expression and motif content of their 39UTRs
was analyzed using sylamer (http://www.ebi.ac.uk/enright/
sylamer), which computes cumulative and hypergeometric p
values associated with small word occurrences in a ranked seq of
larger sequences, in this case 7-mer occurrences across the set of
RefSeq 39UTRs, and using linear regression as implemented in
miReduce [24,25]. For the latter, each motif contained in the
39UTRs is considered to contribute linearly to the fold change
profile, and miReduce iteratively calculates the motifs that
contribute most. The regression coefficient for each motif can be
positive or negative, depending on whether the interaction results
in a suppression or activation of expression of the target gene. In
the case of over-expressing a miRNA, we expect the transcripts
containing motifs complementary to the microRNA seed sequence
to be reduced in expression, so that the motif would have a
negative regression coefficient.
Reverse-Phase Protein Array (RPPA)
Protein lysates were prepared using hot lysis buffer (2% SDS;
0.06 M Tris-Cl, pH 6.8; 5% glycerol) with proteinase and
phosphatase inhibitors (Sigma-Aldrich, St. Louis, MO; Santa
Cruz Biotechnology) and b-mercaptoethanol freshly added.
Lysates were denatured by boiling for 5 min with supernatants
obtained by centrifuging at 13,000 rpm for 7 min at 4uC. Before
arraying on slides, the protein lysates were filtered through 96-well
filter plates with 25 mm pore membranes (Phenix Research
Products, Candler, NC) to remove aggregates. Equal amounts of
lysates were arrayed in triplicate on ONCYTEH AVID
TM
nitrocellulose film slides (Grace Bio-Labs, Bend, Oregon) using a
SpotArray
TM24 Microarray printing system (PerkinElmer, Wal-
tham, MA) under 55–60% humidity. For immuno-staining, the
slides were first incubated at RT in ReBlot Plus Mild Solution
(EMD Millipore, Billerica, MA) for less than 7 min to relax protein
structure and then washed in TBS-T buffer then incubated in
Pierce SEA BLOCK blocking buffer (Thermo Fisher), blocked
with avidin and biotin (Dako, Glostrup, Denmark), and incubated
with either STAT3 (EMD Millipore) or pSTAT3 (S727, Cell
Signaling Technology) antibody at 4uC overnight. Slides were then
washed and incubated with biotinylated secondary antibodies
(Vector Laboratories, Burlingame, CA) for 30 min followed by
blotting with Qdot 655–streptavidin conjugate (Life Technologies)
for 30 min. Slides were scanned with a ProScanArray Microarray
Scanner (PerkinElmer). Protein expression levels were quantified
using MicroVigene
TM (Vigene Tech, Carlisle, MA) software and
normalized for differences in protein loading using Sypro Ruby
TM
(Life Technologies) protein stain signals obtained on a separate
slide printed in the same batch.
miRNA expression profiling of tumor specimens
10–20 mm thick serial sections of 249 surgically resected
NSCLC specimens (including 172 adenocarcinomas and 76
squamous cell carcinomas) were obtained using a Leica cryostat
and homogenized using an Omni TH homogenizer (Omni
International, Kennesaw, GA). Total RNA was isolated using
TRI Reagent (Life Technologies) and quantified using a Nano-
drop 1000 spectrophotometer (Thermo Fisher). RNA quality was
determined on an Agilent 2100 Bioanalyzer (Agilent Technologies,
Santa Clara, CA).
For microRNA analysis, the samples were labeled using the
miRNA Complete Labeling and Hyb Kit and hybridized to
Agilent Human miRNA microarray version 3 chips (Agilent
Technologies), which contains probes for 866 human and 89
human viral microRNAs based on miRBase v12.0 (http://
microrna.sanger.ac.uk). Hybridizations were performed in stain-
less steel SureHyb chambers (G2534A) at 55uC for 22 h, after
which arrays were washed and scanned using an Agilent DNA
Microarray Scanner (Agilent Technologies). miRNA expression
levels were extracted using the Feature Extraction software
(Agilent Technologies) and processed with the bioconductor [26]
package AgiMicroRna to correct for background, remove control
and un-detectable sequences, and quantile normalize and
summarize the data.
Results
Over-expression of miR-337-3p sensitizes NCI-H1155 cells
to paclitaxel and enhances paclitaxel-induced G2/M
arrest
To examine the effect of miR-337-3p on paclitaxel sensitivity in
lung cancer cells, we used miR-337-3p mimic (Dharmacon) to
increase miR-337-3p levels in NCI-H1155 cells, a lung cancer cell
line characterized as moderately resistant to paclitaxel in a
previous study [8]. As shown in Figure 1A, miR-337-3p over-
expression significantly sensitizes cells to paclitaxel treatment,
decreasing the IC50 – defined as the concentration that leads to a
50% decrease of cell viability – from 27.27 nM (95% CI 25.97–
28.90) with control oligo to 14.60 nM (95% CI 14.08–15.15) with
miR-337-3p mimic (p,0.0001). We next tested the dose-
dependence of the effect of miR-337-3p on paclitaxel sensitivity
and cell viability by transfecting NCI-H1155 cells with different
concentrations of either miR-337-3p mimic or control oligo
followed by treatment with either 16 nM paclitaxel or carrier. As
shown in Figure 1B, miR-337-3p mimic significantly sensitizes
cells to paclitaxel relative to the control oligo at concentrations as
low as 0.5 nM (p=0.0168), but does not significantly decrease cell
viability in the absence of paclitaxel at concentrations even as high
as 200 nM. To further evaluate the regulation of paclitaxel
response by miR-337-3p, we examined the effect of miR-337-3p
inactivation on paclitaxel sensitivity in H1155 cells. As shown in
Figure 1C, inactivation of miR-337-3p by miR-337-3p inhibitor
significantly decreases the response of H1155 to paclitaxel
treatment, with relative cell viability increasing by 17.8165.31%
(p ,0.0001), relative to control oligos.
Taxanes bind to the b subunit of tubulin and inhibit the normal
dynamics of microtubule disassembly, leading to stabilized
microtubules and prolonged arrest of cells in the G2/M phase of
the cell cycle and eventually to cell death [27,28]. We compared
the effect of miR-337-3p over-expression on the cell cycle with or
without paclitaxel treatment, at a time point (16 h) before
paclitaxel induced significant apoptosis. As shown in Figure 1D,
in the presence of paclitaxel, miR-337-3p mimic induces a
dramatic G2/M arrest, with a normalized G2/G1 ratio of
R=4.38, relative to R=2.48 for the control oligo, R=2.34 for
miR-337-5p mimic, and R=2.31 for mock transfection, whereas
miR-337-3p does not affect cell cycle distribution in the absence of
paclitaxel.
The above results indicate that miR-337-3p modulates pacli-
taxel sensitivity in NCI-H1155 cells by specifically enhancing cell
arrest in the G2/M phase of the cell cycle without significantly
affecting cell survival alone.
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predicted targets of miR-337-3p are down-regulated at
the mRNA level by miR-337-3p over-expression
In order to comprehensively search for the target genes that
mediate the effect of miR-337-3p on paclitaxel sensitivity of NCI-
H1155 cells, we profiled gene expression by microarray to identify
transcripts that are down-regulated by miR-337-3p over-expres-
sion, since increasing evidence shows that miRNAs regulate target
gene expression through decreasing mRNA levels [29]. The
magnitude of miR-337-3p over-expression (Figure 2A)i s
comparable to the differences in endogenous expression observed
in different tissues and between IMR-90 fetal lung fibroblasts and
HBECs (Figure S1). Since most recent studies support perfect
complementarity between 7-mers in the seed region (covering
positions 1–8) of a mature miRNA with sequences in the 39UTR
of mRNA transcript as a critical determinant of the interaction
between a miRNA and a target gene [30,31], we assessed the
correlation between expression and motif content of mRNA
transcripts based on the occurrence of 7-mers in their 39UTRs. As
shown in Figure 2B, significantly more of the 1,211 genes
containing the 7-mer UAUAGGA complementary to the miR-
337-3p seed sequence – bases 2–8, considered to be the strongest
determinant of miRNA:target interaction – decrease in expression
than increase (p=1.37610
22), among which 32 genes decrease
$2 fold and only 3 genes increase $2 fold (Figure 2D). In
contrast, roughly equal numbers of the 19,262 genes not
containing the 7-mer decrease and increase in expression.
Furthermore, Figures 2C and 2D show that among the
16,384 7-mer motifs occurring in the 39UTRs of human mRNA
transcripts, several are over-represented in the 39UTRs of genes
that decreased in cells transiently transfected with miR-337-3p
mimic relative to a negative control mimic (Figure 2C), with only
10 motifs showing a significant negative correlation between
mRNA expression levels and their presence in 39UTRs
(Figure 2D). 5 of the motifs correspond to the seed region of a
known miRNA (miR-337-3p), including 1 motif corresponding to
bases 2–8 and 4 corresponding to positions 1–7 and 2–7,
consistent with recent work on seed region matches [30,31].
Interestingly, we found that one motif (GUAGGAA) contains a
G:U basepair at position 7, suggesting that the determinants of
miRNA targets may include non-Watson:Crick complementarity.
Figure 2E shows that, although many of the target genes
identified by the 5 motifs overlap, the additional 4 motifs identify
unique targets. Overall, the above results show that a significant
number of genes containing putative miR-337-3p target sites are
down-regulated by miR-337-3p at the mRNA level and highlight
the value of a comprehensive search for miRNA targets based on
7-mer complementarity to the seed region.
Figure 1. Over-expression of miR-337-3p sensitizes NCI-H1155 cells to paclitaxel. (A) Dose-dependent effect of paclitaxel on cell viability in
the presence or absence of miR-337-3p mimic. Cell viability was measured using the MTS assay. (*, p,0.05; **, p,0.01; ***, p,0.001; ns, not
significant) (B) Cell viability as a function of oligo concentration in the presence or absence of paclitaxel. Cell viability was measured using the ATP
concentration assay. (C) Effect of miR-337-3p knockdown with miR-337-3p inhibitor (50 nM) on paclitaxel sensitivity in H1155 cells. Shown is the
relative cell viability in the presence of 16 nM paclitaxel normalized to control oligos. (****, p,0.0001) (D) Cell cycle analysis as a function of miR-337-
3p overexpression and paclitaxel treatment. The fraction of cells in G1, S and G2 phases was estimated using the Watson pragmatic model, with the
ratio of G2 to G1 fractions for paclitaxel treated cells normalized to that observed for control conditions (R=[G2/G1]paclitaxel/[G2/G1]carrier).
doi:10.1371/journal.pone.0039167.g001
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effect of miR-337-3p on paclitaxel sensitivity
Among the genes down-regulated by miR-337-3p, RAP1A and
STAT3, which are down-regulated by 60% and 63% by miR-337-
3p over-expression, respectively, are both predicted to be direct
targets of miR-337-3p (Figure 3A) and are potentially involved in
the regulation of paclitaxel sensitivity. To validate these interac-
tions, we constructed luciferase reporter vectors containing the
wildtype 39UTRs of STAT3 and RAP1A and the corresponding
control 39UTRs with mutations in the first and third nucleotides of
the target site sequences (Figure 3A), which have been shown to
be crucial in disrupting miRNA:target interactions [22]. As shown
in Figure 3B, miR-337-3p over-expression significantly decreased
luciferase activity in cells expressing the wildtype 39UTRs as
compared with no 39UTR or mutated 39UTRs, demonstrating
that miR-337-3p interacts directly with specific sites in the
39UTRs of STAT3 and RAP1A. Figure 3C shows that the effect
of miR-337-3p on mRNA expression levels of the two genes is
coupled with down-regulation of the endogenous protein expres-
sion levels in H1155 cells. We further examined the effect of miR-
337-3p overexpression on STAT3 and RAP1A levels in H1993, a
NSCLC cell line that is defined as paclitaxel-resistant, with an
undefined IC50. As with H1155 cells, miR-337-3p also down-
regulates STAT3 and RAP1A levels at mRNA and protein levels
in H1993 cells, as shown in Figure 3D. These results suggest that
miR-337-3p has a general regulatory effect on STAT3 and
RAP1A expression in lung cancer cells.
In order to evaluate whether STAT3 and RAP1A mediate the
effect of miR-337-3p on paclitaxel sensitivity, we knocked down
each gene individually and both of them together. Figure 4A
shows that knockdown of STAT3 and RAP1A increased the
sensitivity of NCI-H1155 cells to paclitaxel treatment as compared
with control oligos, but did not significantly affect cell survival in
the absence of paclitaxel. Combining the two siRNAs at half the
Figure 2. Predicted targets of miR-337-3p decrease in mRNA expression on over-expression of miR-337-3p. (A) Expression levels of
miR-337-3p after 72 h transfection of NCI-H1155 cells with 50 nM miR-337-3p mimic as measured by qRT-PCR. (B) Histogram of changes in mRNA
expression level as a function of miR-337-3p over-expression. The bars in black show relative frequencies of observed log2 fold changes for all genes,
while the bars in red show the distribution for genes with 39UTRs containing at least one 7-mer corresponding to the miR-337-3p seed region. (C) The
significance landscape plot for 7-mers across all genes, sorted by change in expression, from most decreased to most increased, showing 7-mers that
are highly enriched in the 39UTRs of genes that are decreased in expression. (D) Correlation between mRNA expression and motif content of 39UTRs
induced by miR-337-3p over-expression. Shown are: (1) the 7-mer motif, highlighted to show complementarity to miR-337-3p, (2) the regression
coefficient, (3) the p value, (4) the number of genes containing the motif, (5) the miRNA to which the motif corresponds, with the nucleotide positions
fully complementary to the highlighted sequences in column 1 shown in brackets, and the number of genes that (6) decrease in expression or (7)
increase in expression by $2-fold. In column 6, the number of genes that contain the listed motif, but do not contain the canonical miR-337-3p seed
sequence target, is given in parentheses. (E) Proportional Venn diagram showing the relationship among the genes that decrease $2 fold in
expression and contain one or more of the five 7-mers corresponding to the mature miR-337-3p sequences.
doi:10.1371/journal.pone.0039167.g002
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observed with either siRNA alone (p=0.017 for RAP1A and
p=0.041 for STAT3), which suggests that the combined knock-
down has a synergistic effect on paclitaxel response (Figure 4B).
Moreover, Figure 4C shows that knockdown of STAT3 or RAP1A
significantly enhances the G2/M arrest under paclitaxel treatment
as compared with control oligos, with normalized G2/G1 ratios of
R=3.02 and R=3.70, respectively, relative to R=1.93 for the
controls and comparable to R=4.37 for transfection with the
miR-337-3p mimic.
Increasing evidence supports the application of STAT3
inhibitors, such as cucurbitacin, as therapeutic agents in treating
various cancers. We therefore tested the effect of miR-337-3p
over-expression on the response of NCI-H1155 cells to treatment
with cucurbitacin, the cytotoxicity of which is at least partially
based on the inhibition of STAT3 activity [32,33]. As shown in
Figure 4D, miR-337-3p mimic sensitizes cells to cucurbitacin,
decreasing the IC50 from 1.14 mM (95% CI 1.03–1.28) to
0.37 mM (95% CI 0.33–0.42) (p ,0.0001), indicating that
targeting both STAT3 expression with miR-337-3p mimic and
STAT3 activation with cucurbitacin has a synergistic effect on
cancer cell survival, and suggesting that miR-337-3p may also
serve as an adjuvant to STAT3 inhibitors.
miR-337-3p sensitizes both paclitaxel-sensitive and
paclitaxel–resistant cell lines as well as those from
different histological subtypes
In order to test the generality of the effect of miR-337-3p on
paclitaxel sensitivity in lung cancer cells, we selected five additional
cell lines belonging to different histological subtypes and with
distinct responses to paclitaxel (Table S1). As shown in
Figure 5A, miR-337-3p over-expression sensitized all five cell
lines to paclitaxel treatment, with a larger effect in the cell lines
that are relatively resistant to paclitaxel treatment (upper panels) as
compared to cell lines that are relatively sensitive (lower panels).
miR-337-3p selectively sensitizes cells to taxanes
In order to examine the specificity of miR-337-3p in modulating
sensitivity to paclitaxel, we tested the effect of miR-337-3p over-
expression on the sensitivity of H1155 cells to other chemother-
apeutic agents that are commonly used in the treatment of lung
cancer. As shown in Figure 5B, transient transfection with miR-
337-3p mimic sensitizes NCI-H1155 cells to docetaxel, another
member of the family of taxanes, leading to a greater sensitization
than that observed with paclitaxel (IC50 of 10.22 nM with a 95%
CI 9.68–10.78 for the control oligo and 2.16 nM with a 95% CI
2.02–2.32 for miR-337-3p mimic, p ,0.0001). Figure 5B also
shows that miR-337-3p over-expression does not sensitize cells to
treatment with cisplatin, a platinum-based chemotherapy agent
Figure 3. RAP1A and STAT3 are direct targets of miR-337-3p. (A) miR-337-3p and its predicted interaction with target sites in RAP1A and STAT3.
Shown are the structures and sequences of the miRNA:target interactions for miR-337-3p and the 39UTRs of RAP1A and STAT3, and the predicted free
energy of hybridization. The seed sequence is highlighted in red. Bases altered by site-directed mutagenesis are underlined. (B) Luciferase reporter
assay. NCI-H1155 cells were co-transfected with the indicated oligos and the luciferase reporter vectors. Luciferase and b-galactosidase activities were
measured after 72 h, with luciferase activity normalized to b-galactosidase activity. (C) Expression of RAP1A and STAT3 mRNA and protein levels after
72 h of transfection of NCI-H1155 cells with either 50 nM miR-337-3p, 25 nM siRNA directed against each of the genes or negative control oligos.
Shown are average qRT-PCR results of three independent transfections and representative Western blot images and quantification of band
intensities. (D) RAP1A and STAT3 mRNA and protein expression in NCI-H1993 cells. *, p,0.05; **, p,0.01; ***, p,0.001.
doi:10.1371/journal.pone.0039167.g003
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2.49 mM with a 95% CI 2.22–3.09 for the control oligo to 3.2 mM
with a 95% CI 3.12–3.35 for miR-337-3p mimic), and slightly de-
sensitizes them to treatment with gemcitabine, a nucleoside analog
which arrests cell growth by disrupting the normal DNA
replication and repair (IC50 of 4.59 nM with a 95% CI 3.32–
6.31 for the control oligo to 7.16 nM with a 95% CI 5.22–9.77 for
miR-337-3p mimic, p=0.04). These findings demonstrate the
specificity of miR-337-3p in enhancing the cytotoxicity of
microtubule stabilizing agents, further suggesting that a major
role of miR-337-3p is to regulate microtubule dynamics during
mitosis in lung cancer cells.
Correlation analysis in a panel of NSCLC lines suggests
that STAT3 may be the major endogenous determinant
of intrinsic paclitaxel response
The involvement of STAT3 in tumorigenesis is well recognized
and therapeutic agents specifically inhibiting STAT3 signaling
have been used to treat several types of cancers [34]. However, the
role of STAT3 in lung cancer tumorigenesis and therapy has not
been fully addressed. We therefore investigated the relevance of
STAT3 to the sensitization of lung cancer cells to paclitaxel
treatment, by assessing the correlation between paclitaxel
response, protein levels of total STAT3 and phospho-STAT3
(pSTAT3) and levels of miR-337-3p in a panel of NSCLC cell
lines. As shown in Figure 6A and B, both total STAT3 and
pSTAT3 protein levels are significantly correlated with both
paclitaxel (r=0.44, p=0.013 for STAT3 and r=0.37, p=0.035
for pSTAT3) and docetaxel (r=0.48, p=0.008 for STAT3 and
r=0.043, p=0.017 for pSTAT3) response across the panel of cell
lines. We also attempted to assess the correlation between miR-
337-3p expression levels, taxane response and levels of STAT3
and pSTAT3, but miR-337-3p was not detectable in most of the
lung cancer cell lines, and therefore not amenable to such an
analysis (data not shown). Overall, the above results suggest that
the endogenous expression of STAT3 plays an important role in
determining the intrinsic sensitivity of lung cancer cells to taxane
treatment, and that the expression levels of STAT3 may serve as a
biomarker for predicting taxane response in NSCLC.
Tumor levels of STAT3 and miR-337-3p are correlated
with overall survival in NSCLC patients
Shown in Figure 7 are survival curves for the patients with the
lowest and highest tumor expression levels of STAT3 and miR-
337-3p, as measured by Illumina and Agilent microarray,
respectively. Mean survival in the low and high STAT3 groups
(nL=29, nH=30) were 6.7 years and 4.2 years, respectively, with
a hazard ratio of 1.54 (95% CI 0.71–3.35), and a p value of 0.28,
assessed by Mantel-Cox log-rank test. Mean survival in the low
and high miR-337-3p groups (nL=30; nH=32) were 4.2 years
Figure 4. siRNA knockdown of regulatory targets of miR-337-3p sensitizes NCI-H1155 cells to paclitaxel. (A) Effect of knockdown of
RAP1A and STAT3 expression by siRNA on cell viability in the presence and absence of paclitaxel. Shown in red is cell viability in 16 nM paclitaxel
normalized to viability in carrier as a function of increasing concentrations of siRNAs against RAP1A or STAT3. Shown in black is cell viability in the
absence of paclitaxel. (B) Effect of combined knockdown of RAP1A and STAT3 on paclitaxel sensitivity. Shown is the relative cell viability in the
presence 16 nM paclitaxel normalized to control oligos. (C) Knockdown of STAT3 and RAP1A enhances paclitaxel-induced G2/M arrest as measured by
flow cytometry. The ratio (R) of the G2 to G1 fractions induced by paclitaxel treatment was determined as above. (D) Cell viability as a function of oligo
concentration (miR-337-3p mimic or negative control mimic) in the presence of cucurbitacin. *, p,0.05.
doi:10.1371/journal.pone.0039167.g004
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0.30–1.38) and a p value of 0.26, assessed as above. Although the
results did not reach statistical significance by Mantel-Cox test,
there is a clear trend indicating that high miR-337-3p levels and
low STAT3 levels are correlated with increased overall survival.
Discussion
In this study, we define a novel pathway by which cellular
sensitivity to paclitaxel is regulated by miR-337-3p and its two
direct regulatory targets, STAT3 and RAP1A. We have shown that
miR-337-3p sensitizes lung cancer cell lines to paclitaxel treatment
by directly down-regulating the expression of STAT3 and RAP1A,
leading to increased cell death by enhancing the paclitaxel-
induced arrest of cells in the G2/M phase of the cell cycle. In
addition, we are the first to define the regulation of STAT3 and
RAP1A by a single miRNA in the context of lung cancer, and
provide the first preliminary evidence showing that STAT3
expression is an intrinsic determinant of paclitaxel response in
lung cancer cells. Given the increasing evidence supporting clinical
application of STAT3 inhibitors as therapeutic agents in treating
various cancers [32,33], our findings underscore the relevance of
targeting STAT3 in lung cancer therapy from at least two
perspectives. First, our findings provide a potential alternative,
the use of miR-337-3p mimic, to target STAT3. Second, our
findings provide support for combining STAT3 inhibitors with
paclitaxel in order to improve response to lung cancer treatment.
Previous studies indicate that miRNAs act as fine-tuning
regulators of protein expression. As we observed in this study,
miR-337-3p decreases the mRNA and protein levels of STAT3
and RAP1A less than specific siRNA oligos. However, the fact that
one miRNA can disrupt multiple pathways that are involved in
regulating cancer cell survival or drug response in the same
direction both minimizes the chances of off-target effects and
decreases the possibility of acquired resistance to miRNA-based
therapeutic strategies relative to traditional therapeutic approach-
es, which may therefore increase the proportion of cancer patients
that will respond to such treatments and the duration of that
response. This is especially important given the fact that individual
therapeutic agents currently used exhibit resistance rates ranging
from 50%-80% [35]. Our examination suggests that miR-337-3p
sensitizes lung cancer cells with different tumorigenic and
molecular backgrounds, supporting the potential of miR-337-3p
Figure 5. miR-337-3p over-expression selectively sensitizes cells to drugs that affect microtubule dynamics. (A) Five cell lines were
transfected with 50 nM miR-337-3p mimic or negative control mimic oligo for 72 h. Cells were then treated with increasing concentrations of
paclitaxel for an additional 72 h. Relative cell viability was measured and calculated as above. (B) NCI-H1155 cells were treated with 50 nM miR-337-
3p mimic in the presence of increasing concentrations of docetaxel, cisplatin and gemcitabine as described above. miR-337-3p mimic sensitizes calls
to docetaxel relative to control oligos, shifting the dose-response curve to the left, but does not sensitize cells to cisplatin and gemcitabine.
doi:10.1371/journal.pone.0039167.g005
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PLoS ONE | www.plosone.org 8 June 2012 | Volume 7 | Issue 6 | e39167Figure 6. STAT3 and pSTAT3 levels correlate with resistance to taxanes in a panel of NSCLC cell lines. STAT3 and pSTAT3 protein levels
were measured by RPPA. IC50s were measured by MTS assay. Protein levels plotted against IC50s for (A) paclitaxel and (B) docetaxel in 25 NSCLC cell
lines. Correlations assumed that data were sampled from Gaussian populations (Pearson), and significance was assessed by one-tailed test.
doi:10.1371/journal.pone.0039167.g006
Figure 7. Overall survival of NSCLC patients correlates with tumor levels of STAT3 and miR-337-3p. Shown are survival curves for
groups of NSCLC patients with the lowest and highest tumor expression levels of STAT3 and miR-337-3p. Mean survival times in the low (nL=29,
green) and high STAT3 (nH=30, red) groups were 6.7 years and 4.2 years, respectively, with a hazard ratio of 1.54 (95% CI 0.71–3.35), and a p value of
0.28, while mean survival times in the low (nL=30, green) and high miR-337-3p (nH=32, red) groups were 4.2 years and 6.5 years, respectively, with a
hazard ratio of 0.65 (95% CI 0.30–1.38) and a p value of 0.26. Statistical significance was assessed by Mantel-Cox log-rank test.
doi:10.1371/journal.pone.0039167.g007
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the treatment of lung cancer.
STAT3 is a well-characterized transcription factor that has been
demonstrated to contribute to various processes of tumorigenesis,
such as tumor cell survival and proliferation, invasion, angiogen-
esis and drug resistance [36]. Many of its target genes, such as
cyclin D1, c-myc, Bcl-2, survivin and p21
cip1 have been shown to
control tumor cell survival and proliferation [37,38]. However, the
mechanisms by which STAT3 regulates drug resistance have not
been clearly defined. Hawthorne et al., showed that STAT3
activation induced subsequent up-regulation of p21
cip1 and
paclitaxel resistance in breast cancer [39]. Real et al., showed that
treatment of a metastatic breast cancer cell line with a dominant-
negative form of STAT3 sensitized cells to paclitaxel and inhibited
STAT3-mediated Bcl-2 induction [40]. These studies, however,
did not demonstrate direct involvement of either p21
cip1 or Bcl-2
in mediating STAT3-induced paclitaxel resistance. Other studies
have demonstrated pathways by which STAT3 modulates
microtubule dynamics independent of its function as a transcrip-
tion factor. For example, Ng, et al. showed that STAT3 regulates
cell migration in murine embryonic fibroblast (MEF) cells by
directly interacting with stathmin [41], a protein that binds the a/
b-tubulin heterodimers to facilitate the depolymerization of
microtubules. This study also shows that the interaction of STAT3
with stathmin does not significantly affect the cell cycle distribu-
tion, which is consistent with our observations showing that
STAT3 knockdown alone does not affect cell cycle distribution. A
more recent study showed the physical association of pSTAT3
with tubulin, suggesting another possible mechanism of STAT3
modulation of paclitaxel sensitivity [42].
RAP1A is one of the two isoforms of RAP1 and has also been
implicated in regulating microtubule dynamics. RAP1 has been
indicated to activate the MAPK/ERK pathway [43,44,45], which
has been implicated in regulating microtubule dynamics by
phosphorylating microtubule-associated proteins MAP2 and
MAP4 [46,47]. RAP1 has also been shown to be important for
interactions between cells and the extracellular matrix [48], and
independent work has connected integrity of the extracellular
matrix to sensitivity to paclitaxel [49].
Based on the above evidence, we propose the model for the
regulation of paclitaxel sensitivity by STAT3 and RAP1A shown
in Figure 8. In this model, in normal microtubule dynamics,
STAT3 acts as an antagonist of microtubule depolymerization by
interacting with stathmin, and RAP1A inhibits microtubule
polymerization through activation of ERK/MAPK and phos-
phorylation of MAP2 and MAP4. Knockdown of either RAP1A or
STAT3 alters the normal dynamics, making the cell vulnerable to
perturbations caused by microtubule targeting agents. In the case
of both taxane treatment and RAP1A or STAT3 depletion, the
altered microtubule dynamics resulting from reduced RAP1A and
STAT3 expression and the stabilization induced by taxanes have a
synergistic effect on abrogating normal microtubule function,
leading to enhanced G2/M arrest and eventually cell death.
Further studies are clearly needed to validate the proposed model.
Another interesting observation in our study is that neither the
over-expression of miR-337-3p nor the specific knockdown of
STAT3 and RAP1A significantly decrease cell viability or induce
G2/M arrest alone, but rather enhance G2/M arrest and cell
death only under conditions of paclitaxel treatment, even though
its regulatory targets, STAT3 and RAP1A, have been indicated to
promote cancer cell survival and proliferation [50,51]. This
observation can be explained, at least partially, by the diversity of
the STAT3 and RAP1A functions. The diverse and seemingly
contradictory functions of STAT3 in different cellular contexts
have been well documented in previous studies [36,52], demon-
strating that, although STAT3 targets multiple genes involved in
tumorigenesis, not all of the target genes are expressed in a
STAT3-dependent manner in all tumors. Rather, STAT3 controls
distinct subsets of genes in different intracellular contexts. It is
therefore possible that, in at least a subset of lung tumors, STAT3
primarily controls pathway(s) that specifically affect taxane
sensitivity, but does not significantly affect the function of genes
directly involved in controlling tumor cell survival. Evidence from
our study supporting this possibility is that we did not observe
down-regulation of p21
cip1, a major target of STAT3 transcrip-
tional activation, following either STAT3 siRNA or miR-337-3p
transfections (data not shown). This diversity of STAT3 functions
in different tumor cellular contexts certainly warrants further
investigation.
In summary, in this study we demonstrate for the first time the
involvement of miR-337-3p in modulating drug resistance of lung
cancer cells and define a novel regulatory pathway modulating
paclitaxel response in lung cancer cells mediated by miR-337-3p
down-regulation of STAT3 and RAP1A, which has potential
significance for the prediction and improvement of therapeutic
response to taxane treatment in NSCLCs. Further work is clearly
required to elucidate the genes down-stream of STAT3 and RAP1A
that mediate their effect on paclitaxel sensitivity and to define the
feasibility and efficacy of miR-337-3p mimic delivery in the
context of taxane-based therapies.
Supporting Information
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